Canaccord raised the firm’s price target on Compass Therapeutics (CMPX) to $13 from $10 and keeps a Buy rating on the shares. The firm said they see upside to $13 and downside to $4 on upcoming Phase 2/3 data for tovecimig + paclitaxel expected end of 1Q26. They see a low bar vs paclitaxel monotherapy, and note Compass demonstrated a statistically significant benefit for response rate as well as believing safety is manageable,
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics: Strengthening Clinical Pipeline and 2026 Milestones Underscore Buy Rating and Upside Potential
- Compass Therapeutics: Strong Cash Position and 2026 Clinical Catalysts Underpin Reiterated Buy Rating
- Compass Therapeutics provides corporate update
- Compass Therapeutics details cash runway and pipeline progress
- Compass Therapeutics appoints Arjun Prasad as CCO, Cynthia Sirard as CMO